<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar1528</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>The role of hypoxia in rheumatoid tendon disease</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Sivakumar</snm>
               <fnm>B</fnm>
               <insr iid="I1"/>
               <insr iid="I2"/>
            </au>
            <au id="A2">
               <snm>Kang</snm>
               <fnm>N</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Taylor</snm>
               <fnm>P</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A4">
               <snm>Paleolog</snm>
               <fnm>EM</fnm>
               <insr iid="I2"/>
               <insr iid="I3"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Restoration of Appearance of Function Trust, Northwood, UK</p>
            </ins>
            <ins id="I2">
               <p>Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College, London, UK</p>
            </ins>
            <ins id="I3">
               <p>Division of Surgery, Anaesthetics and Intensive Care, Faculty of Medicine, Imperial College, London, UK</p>
            </ins>
         </insg>
         <source>Arthritis Research &amp; Therapy</source>
         <supplement>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <sponsor>
               <note>The organizer would like to thank the following companies who have generously supported the meeting: Abbott Immunology (Main sponsor), Bristol-Myers Squibb, Schering-Plough, Wyeth, AstraZeneca, MSD, Amgen</note>
            </sponsor>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <location>Glasgow, UK</location>
            <date-range>24-27 February 2005</date-range>
         </conference>
         <issn>1478-6354</issn>
         <pubdate>2005</pubdate>
         <volume>7</volume>
         <issue>Suppl 1</issue>
         <fpage>P7</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar1528</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>11</day>
               <month>1</month>
               <year>2005</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>17</day>
               <month>2</month>
               <year>2005</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2005</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Background</p>
         </st>
         <p>Tendon disease is often the first presentation of rheumatoid arthritis (RA). Tenosynovial proliferation results in scarring and adhesion formation. Synovial invasion into tendons occurs in 50% of cases and is associated with multiple tendon ruptures and a poorer prognosis. Recent work on diseased joints suggests that hypoxia may play a key role in synovial invasion. We hypothesised that hypoxia promotes and maintains the inflammatory response in RA tenosynovium via neovascularisation.</p>
      </sec>
      <sec>
         <st>
            <p>Objectives</p>
         </st>
         <p>To measure oxygen tension (pO<sub>2</sub>) within the synovium of rheumatoid tendons and joints <it>in vivo</it>. To study markers of hypoxia and neovascularisation in invasive and non-invasive tendon synovium by immunohistochemistry. To investigate the effects of hypoxia on <it>in vitro </it>cultures of invasive and non-invasive tenosynovium.</p>
      </sec>
      <sec>
         <st>
            <p>Methods</p>
         </st>
         <p>Patients undergoing elective hand surgery for RA were recruited into the study. <it>In vivo </it>oxygen tension measurements were taken intra-operatively using an established microelectrode technique. Readings were taken from tendon and joint synovium. Diseased tissue was harvested from areas of oxygen sampling for immunohistochemical analysis of CD31 expression.</p>
         <p>Tissue was also harvested from invasive and non-invasive tenosynovium. Joint tissue was used as a control. Serial sections of tissue were stained for the pro-angiogenic factor vascular endothelial growth factor (VEGF) and the hypoxia-regulated transcription factor hypoxia inducible factor (HIF)-2&#945;.</p>
         <p>Separate tissue from these three areas of interest was enzymatically digested and cultured in hypoxic (1% oxygen) and normoxic (21% oxygen) conditions. Supernatants were harvested at 24 hours and analysed for expression of key inflammatory cytokines by ELISA.</p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>We observed profound hypoxia in the synovium of RA tendons and joints <it>in vivo </it>despite immunohistochemical evidence of markedly increased vascularity, measured as expression of CD31. Immunohistochemical analysis revealed twofold greater VEGF expression in tenosynovium (<it>P </it>&lt; 0.05), compared with joint synovium from the same patient. Levels of HIF-2&#945; were found to be similar in tendon and joint synovium.</p>
         <p>One of the consequences of synovial hypoxia could be the modulation of inflammatory and angiogenic cytokines. We found that hypoxia upregulated <it>in vitro </it>expression of pro-angiogenic cytokine VEGF in both joint and tenosynovial cultures (<it>P </it>&lt; 0.05) by an average of 128%, and in parallel increased levels of the pro-inflammatory cytokine tumour necrosis factor alpha by an average of 105%. In contrast, hypoxia downregulated expression of monocyte chemoattractant protein-1 (<it>P </it>&lt; 0.05) by an average of 44%.</p>
      </sec>
      <sec>
         <st>
            <p>Conclusions</p>
         </st>
         <p>Hypoxia is a feature of rheumatoid tenosynovitis. Key cytokines are regulated by hypoxia in this disease process. HIF-2&#945; may represent the link between hypoxia and VEGF-driven angiogenesis in rheumatoid tendon disease.</p>
      </sec>
   </bdy>
   <bm>
      <ack>
         <sec>
            <st>
               <p>Acknowledgements</p>
            </st>
            <p>BS is a Royal College of Surgeons of England Research Fellow. The Kennedy Institute of Rheumatology receives a core grant from arc.</p>
         </sec>
      </ack>
   </bm>
</art>
